Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
IRF2BP2 encodes an interferon regulatory factor-2 (IRF2) binding protein that interacts with the C-terminal transcriptional repression domain of IRF2. Additionally we are shipping IRF2BP2 Antibodies (64) and and many more products for this protein.
Showing 3 out of 4 products:
A novel IRFBP2 mutation was identified in a family with autosomal dominant CVID (show TNFRSF13B ELISA Kits). Transduction experiments suggest that the mutant protein has an effect on B-cell differentiation and is likely a monogenic cause of the family's CVID (show TNFRSF13B ELISA Kits) phenotype.
ETO2 and IRF2BP2 interacting with the NCOR1/SMRT co-repressor complex, suppresses the expression of erythroid genes until erythroid differentiation.
A deletion variant that lowers IRF2BP2 expression predisposes to coronary artery disease in humans.
analysis of an IRF2BP2-CDX1 (show CDX1 ELISA Kits) fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma
Nuclear localization of IRF2BP2 depends on phosphorylation near a conserved NLS (show ALDH1A2 ELISA Kits). Changes in phosphorylation status likely control nucleocytoplasmic localization of IRF2BP2 during muscle differentiation.
results indicate that DIF-1 plays a key role in breast cancer cell survival
Data demonstrate that IRF-2BP2 is a negative regulator of the NFAT1 (show NFAT1 ELISA Kits) transcription factor and suggest that NFAT1 (show NFAT1 ELISA Kits) repression occurs at the transcriptional level.
IRF2BP2 works with TEAD transcription factors to upregul (show VEGFA ELISA Kits)ate the expression of VEGFA in skeletal and cardiac muscle. IRF2BP2 protein levels are increased in response to tissue ischemia.
Identification of IRF-2 binding protein 1 and IRF-2 binding protein 2 as co-repressor molecules for interferon regulatory factor-2 (show IRF2 ELISA Kits).
Irf2bp2 gene expression was decreased in CD4 (show CD4 ELISA Kits) T cells upon activation. Ectopic expression of IRF2BP2 led to a reduction in CD25 (show IL2RA ELISA Kits) expression and STAT5 (show STAT5A ELISA Kits) phosphorylation, along with an impaired proliferative capacity. IRF2BP2 overexpression in differentiated Th cells resulted in reduced IL-4 (show IL4 ELISA Kits) and pro-TGF-beta (show TGFB1 ELISA Kits) production in Th2 and iTregs but had no effect on IFN-gamma (show IFNG ELISA Kits) or IL-17 (show IL17A ELISA Kits) expression in Th1 (show HAND1 ELISA Kits) and Th17 cells, respectively.
IRF2BP2 as a novel negative regulator in controlling pathological Cardiac Hypertrophy at the transcriptional level was defined.
Ablation of IRF2BP2 in macrophages worsens atherosclerosis in mice.
IRF2BP2 is a novel ischemia-induced coactivator of VEGFA (show VEGFA ELISA Kits) expression that may contribute to revascularization of ischemic cardiac and skeletal muscles.
This gene encodes an interferon regulatory factor-2 (IRF2) binding protein that interacts with the C-terminal transcriptional repression domain of IRF2. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
IRF-2-binding protein 2
, interferon regulatory factor 2-binding protein 2
, putative nuclear protein of bilaterial origin (49.6 kD) (5N852)